Pfizer expects fewer people needed for Lyme disease vaccine trial
Pfizer said it expects fewer people will be needed to complete its Phase III trial of Valneva’s Lyme disease vaccine candidate than originally thought.
The so-called VALOR study will enroll about 9,000 people aged five or older to gather efficacy, a Pfizer spokesperson said in an emailed statement. Fierce Biotech reported Tuesday that Pfizer vaccine R&D chief Annaliesa Anderson said enrollment would be “much less” than the original 18,000-person estimate.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
